Clinical Trial Update: A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating dabrafenib and/or trametinib in relapsed or refractory multiple myeloma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dabrafenib (Tafinlar) (dabrafenib)
• Trametinib (Mekinist) (trametinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING